Your browser doesn't support javascript.
loading
Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.
Iida, Shinsuke; Sunami, Kazutaka; Mishima, Yuko; Fujii, Taku; Kato, Hitomi; Terao, Takumi; Matsuzawa, Yuki; Matsubara, Mari; Crossman, Timothy; Kremer, Brandon E; Gupta, Ira.
  • Iida S; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan. iida@med.nagoya-cu.ac.jp.
  • Sunami K; Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
  • Mishima Y; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Fujii T; GSK, Tokyo, Japan.
  • Kato H; GSK, Tokyo, Japan.
  • Terao T; GSK, Tokyo, Japan.
  • Matsuzawa Y; GSK, Tokyo, Japan.
  • Matsubara M; GSK, Tokyo, Japan.
  • Crossman T; Oncology Global Clinical Development, GSK, Stevenage, UK.
  • Kremer BE; Clinical Development, GSK, Upper Providence, PA, USA.
  • Gupta I; Clinical Oncology, GSK, Upper Providence, PA, USA.
Int J Hematol ; 118(5): 596-608, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37668832
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Mieloma Múltiple Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Mieloma Múltiple Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article